Why Artiva Biotherapeutics, Inc.’s (ARTV) Stock Is Down 30.19%
As of Tuesday, October 27, Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 30.19%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Commentary & Analysis
Why Artiva Biotherapeutics, Inc.’s (ARTV) Stock Is Up 7.81%
As of Tuesday, October 20, Artiva Biotherapeutics, Inc.’s ARTV share price has surged by 7.81%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Artiva Biotherapeutics, Inc.’s (ARTV) Stock Is Down 5.80%
As of Wednesday, October 14, Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 5.80%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Artiva Biotherapeutics, Inc.’s (ARTV) Stock Is Down 5.91%
As of Tuesday, October 13, Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 5.91%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Artiva Biotherapeutics, Inc.’s (ARTV) Stock Is Down 5.14%
As of Thursday, October 08, Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 5.14%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ARTV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $201.9 | $214.3 | 29% |
|
| Shares Out (Mil) | 39.4 | 53.9 | 42% |
|
| Institutional Ownership | 89.8% | 92.9% | 58% |
|
| Float (Mil) | 19.6 | 41.4 | 28% |
|
| Beta | 2.18 | 0.96 | 93% |
|
| Avg Daily Volume (000s) | 1,951 | 506 | 79% |
|
| Price Change (52-week) |
15.0% | 43.9% | 64% |
|
| Growth | ARTV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (36.0%) | (10.1%) | 11% |
|
| EPS (5yr) | 34.5% | 15.8% | 85 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.0%) | (15.7%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.534) | ($2.640) | ($1.984) | |
| Month Ago EPS | ($0.534) | ($2.510) | ($2.608) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.523) | ($2.433) | ($2.815) | |
| Year/Year Chg | (15.8%) | (23.1%) | (49.0%) | |
| Financials | ARTV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($91) | ($44) | 12% |
|
| EPS (TTM) | ($3.208) | ($1.500) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($75) | ($34) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $273 | $1 | 86% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $4 | 26% |
|
| Enterprise Value (Q1) (Mil) | $211 | $172 | 27% |
|
| Valuation | ARTV | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.58 | 2.00 | 13% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ARTV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (63.5%) | na |
|
| ROA | (33.8%) | (47.5%) | 15% |
|
| ROE | (36.6%) | (53.3%) | 18% |
|
| Liabilities to Assets | 5.7% | 29.6% | 3% |
|
| F-Score | 4 | 2 | 33% |
|
Artiva Biotherapeutics, Inc. did not pass any screens on 11/5/2026.
